Glenmark

Glenmark inks deal with SaNOtize for COVID treatment nasal spray in India, other Asian markets

The phase III clinical trial for Nitric Oxide Nasal Spray is expected to be completed, followed by commercial launch under the brand name FabiSpray in India, by the fourth quarter of 2021.

published on : 2nd August 2021

Glenmark Life Sciences IPO to open on July 27; price band set at Rs 695-720/share

The public issue will have fresh issue of equity shares worth up to Rs 1,060 crore and sale of up to 63 lakh equity shares by Glenmark Pharma.

published on : 21st July 2021

Glenmark Pharma gets USFDA nod for Arformoterol Tartrate Inhalation Solution

The approved product is a generic version of Brovana Inhalation Solution, 15 mcg/2 mL, of Sunovion Pharmaceuticals Inc.

published on : 23rd June 2021

 Glenmark Q4 net profit up 6 per cent at Rs 233.87 crore

The company had posted a net profit of Rs 220.30 crore in the corresponding period of the previous fiscal, Glenmark said in a late regulatory filing on Friday.

published on : 29th May 2021

Glenmark Pharma gets USFDA nod for Icatibant injection for angioedema treatment

Hereditary angioedema is a disorder that results in recurrent attacks of severe swelling.

published on : 24th May 2021

Glenmark Life Sciences​ files preliminary papers for IPO with SEBI

The board of directors of Glenmark Pharmaceuticals Ltd during its meeting on April 16 approved the offer for sale of up to 73,05,245 equity shares of Rs 2 apiece as part of the IPO.

published on : 17th April 2021

Glenmark gets USD 40 million COVID credit line from International Finance Corporation

The loan to Glenmark will help it increase the availability of affordable, quality medicines in the country as well in other countries, including treatment for the pandemic.

published on : 23rd March 2021